When James Rosen became president and CEO of Artizan Biosciences, it was a clear signal that Artizan was onto something big.
Artizan’s initial product uses monoclonal antibodies to disrupt the bacteria that cause inflammation in the bowel.
Recently Artizan raised $11 million in funding from investors that included Connecticut Innovations and Elm Street Ventures. But the key to the deal was an agreement allowing Biohaven Therapeutics the rights to commercialize three Artizan products.